5-Amino-1MQ Dosage Chart
Community-cited oral protocols paired with the editorial context this preclinical-only molecule requires.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied in animal obesity models. Despite its rapid adoption by online research-peptide retailers, there are essentially no published human safety, efficacy, or pharmacokinetic data. Every dose recommendation circulating online is extrapolated from rodent studies. We are publishing this chart so readers who encounter the peptide elsewhere have access to honest context — but our editorial position is that 5-Amino-1MQ should not be treated as a validated therapy.
5-Amino-1MQ at a Glance
| Typical dose (community-cited) | 50–150 mg/day oral |
|---|---|
| Cycle length (community-cited) | 8–12 weeks |
| Route | Oral capsule |
| FDA status | Not FDA-approved. No human trials published. Research-only. |
| Source quality | Preclinical animal data only. No human PK, no human safety, no human dose-finding. |
| Safety status | Insufficient data to characterize human safety. |
5-Amino-1MQ Dosing by Use Case
Commonly cited protocols vary by what 5-Amino-1MQ is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Metabolic / fat loss (community use) | 50–150 mg | Once daily oral | 8–12 weeks | All protocols are community-derived from preclinical rodent data. |
5-Amino-1MQ has zero published human safety data. Every dose recommendation is extrapolated from animal studies — the absence of harm signals reflects the absence of trials, not safety.
- •No human pharmacokinetic data has been published.
- •No human safety trials have been published.
- •NNMT inhibition has systemic implications for one-carbon metabolism, NAD/methylation balance, and gene expression — long-term effects in humans are unknown.
- •Not FDA-approved, not in any approved trial pathway as of April 2026.
- •We do not recommend treating 5-Amino-1MQ as a validated weight-loss or anti-aging therapy.
- •Pregnancy or breastfeeding
- •Anyone without medical supervision
- •Metabolic disorders affecting one-carbon metabolism (folate, B12, methylation pathways)
5-Amino-1MQ Dosing FAQ
Because 5-Amino-1MQ is being marketed online and people are searching for dose information. Publishing accurate safety context alongside the commonly-cited doses is more protective than leaving the topic uncovered. The safety section above is the part of this page we want readers to actually act on.
Animal studies of NNMT inhibition show metabolic effects in obese mice. Whether 5-Amino-1MQ specifically produces meaningful weight loss in humans, at what doses, and with what side-effect profile — these are unanswered questions. Community 'before and after' anecdotes are not evidence.
Yes. Semaglutide, tirzepatide, and (with appropriate clinical supervision) retatrutide all have substantial human trial data. Tesamorelin has FDA-approved data for visceral fat reduction. Any of these has stronger evidence than 5-Amino-1MQ.
Sources
Related Dosage Charts
Want the full 5-Amino-1MQ guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for 5-Amino-1MQ therapy.
See 5-Amino-1MQ guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.